GlobeNewsWire
14 Sept 2026, 06:40 UTC · 1h ago
Verdict
Headline takes no side. We score CLLS +0.20 across three claims.
Our read: bullish.
CLLS score
+0.20
More positive than 54% of ticker scores this week
Price reaction
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen
What the story claims
3 claims · scored −1 bearish … +1 bullish
Cellectis is exiting the development of its CAR T-cell therapy candidates lasme-cel and eti-cel due to a shrinking addressable market and increased competition.
More negative than 91% of claims this week
The operational realignment and exit of CAR T programs are designed to extend the company's cash runway into the second half of 2028.
So whatExtended cash runway reduces immediate dilution risk and provides the financial stability needed to reach the next set of clinical milestones.
Continue reading
5 related stories
Top 1 mover · tap to explore
More positive than 77% of claims this week
The company is pivoting its strategic focus to become an in vivo gene editing company, prioritizing candidates .HEAL-101 and .HEAL-201.
More positive than 66% of claims this week
Which stocks this story touches
More positive than 54% of ticker scores this week
The company is pivoting to a strategic in vivo gene editing focus to extend its cash runway and target high-potential candidates, though it is exiting some current product developments.
Near neutral — 90% of ticker scores this week are stronger
Mentioned only as an existing cell therapy partner without any news affecting its valuation.
Near neutral — 90% of ticker scores this week are stronger
Mentioned only as an existing cell therapy partner without any news affecting its valuation.
Near neutral — 90% of ticker scores this week are stronger
Mentioned only as an existing cell therapy partner without any news affecting its valuation.
More positive than 34% of relationship scores this week
[mutual] Cellectis maintains an existing cell therapy partnership with AstraZeneca.
More positive than 34% of relationship scores this week
[mutual] Cellectis maintains an existing cell therapy partnership with Allogene.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
6h ago
More positive than 34% of relationship scores this week
[mutual] Cellectis maintains an existing cell therapy partnership with Iovance.
Price reaction
Expected +0.20Actual —
CLLS hasn't traded since this ran. Last close $3.10 (Sep 11); the reaction starts at the next open.
CLLS chart →
